Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Year: 2018
Type: article
Abstract: Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.
Source: Nature Communications
Authors: Camilo E. Quevedo, Abimael Cruz-Migoni, Nicolas Bery, Ami Miller, Tomoyuki Tanaka, Donna Petch, Carole J. R. Bataille, Lydia Y. W. Lee, Phillip S. Fallon, Hanna Tulmin, Matthias T. Ehebauer, Narcis Fernandez-Fuentes, Angela J. Russell, Stephen B. Carr, Simon E. V. Phillips, Terence H. Rabbitts
Institutions: John Radcliffe Hospital, University of Oxford, MRC Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, Rutherford Appleton Laboratory, Research Complex at Harwell, St James's University Hospital, Sanofi (Japan), Domainex (United Kingdom), Centre for Human Genetics, Aberystwyth University, Institute of Biological, Environmental and Rural Sciences
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,736
OpenAlex ID: W2886738135
